Literature DB >> 6814746

Influence of underfeeding during the "critical period" or thereafter on carcinogen-induced mammary tumors in rats.

P W Sylvester, C F Aylsworth, D A Van Vugt, J Meites.   

Abstract

Normal cycling virgin female Sprague-Dawley rats were divided into different treatment groups and subjected to half ad libitum feed intake for 2 or 4 weeks at consecutive periods of time before and/or after administration of 7,12-dimethylbenz(a)anthracene (DMBA) and then were returned to full-feed. All rats at the end of their respective under-feeding periods showed reductions in serum prolactin and cessation of estrous cycles. However, only rats underfed 1 week prior to and 1 week after DMBA administration showed significant reductions in mammary tumorigenesis or the entire 21 weeks of the experiment when compared to full-feed controls. Rat groups underfed during subsequent weeks after DMBA administration showed no alterations in mammary tumor development as compared to full-fed controls. These results demonstrate that inhibition and perhaps permanent suppression of mammary tumorigenesis occurred only in rats underfed 1 week before and 1 week after DMBA administration. The inhibitory effects produced by this under-feeding regimen on mammary tumorigenesis may be mediated by suppression of prolactin and estrogen secretion.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814746

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Dietary energy restriction in breast cancer prevention.

Authors:  Henry J Thompson; Zongjian Zhu; Weiqin Jiang
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

2.  Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis.

Authors:  D E Blask; S M Hill; K M Orstead; J S Massa
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

Review 3.  Weight cycling and cancer: weighing the evidence of intermittent caloric restriction and cancer risk.

Authors:  Henry J Thompson; Anne McTiernan
Journal:  Cancer Prev Res (Phila)       Date:  2011-10-07

Review 4.  Oxidants, antioxidants, and the degenerative diseases of aging.

Authors:  B N Ames; M K Shigenaga; T M Hagen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

5.  Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver.

Authors:  B Grasl-Kraupp; W Bursch; B Ruttkay-Nedecky; A Wagner; B Lauer; R Schulte-Hermann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

Review 6.  Could Intermittent Energy Restriction and Intermittent Fasting Reduce Rates of Cancer in Obese, Overweight, and Normal-Weight Subjects? A Summary of Evidence.

Authors:  Michelle N Harvie; Tony Howell
Journal:  Adv Nutr       Date:  2016-07-15       Impact factor: 8.701

7.  Short-term calorie restriction feminizes the mRNA profiles of drug metabolizing enzymes and transporters in livers of mice.

Authors:  Zidong Donna Fu; Curtis D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  2013-11-13       Impact factor: 4.219

8.  Transient caloric restriction and cancer risk (The Netherlands).

Authors:  Sjoerd G Elias; Petra H M Peeters; Diederick E Grobbee; Paulus A H van Noord
Journal:  Cancer Causes Control       Date:  2007-02       Impact factor: 2.506

Review 9.  DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis.

Authors:  B N Ames; M K Shigenaga; L S Gold
Journal:  Environ Health Perspect       Date:  1993-12       Impact factor: 9.031

Review 10.  A Systematic Literature Review and Meta-Regression Analysis on Early-Life Energy Restriction and Cancer Risk in Humans.

Authors:  Rachel J J Elands; Colinda C J M Simons; Martien van Dongen; Leo J Schouten; Bas A J Verhage; Piet A van den Brandt; Matty P Weijenberg
Journal:  PLoS One       Date:  2016-09-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.